Efalizumab, which targeted αL integrins, was withdrawn from the market because of multiple cases of progressive multifocal leukoencephalopathy (PML), said to be involved with inhibition of α4-containing integrins and αLβ2 (96). Here, AFM is linked to progressive multifocal leukoencephalopathy.